This is a self-archived version of an original article. This version may differ from the original in pagination and typographic details.

Author(s): Solli, Guro S.; Sandbakk, Silvana B.; Noordhof, Dionne A.; Ihalainen, Johanna K.; Sandbakk, Øyvind

Title: Changes in Self-Reported Physical Fitness, Performance, and Side Effects Across the Phases of the Menstrual Cycle Among Competitive Endurance Athletes

Year: 2020

Version: Accepted version (Final draft)

Copyright: © 2020 Human Kinetics, Inc.

Rights: In Copyright

Rights url: <http://rightsstatements.org/page/InC/1.0/?language=en>

Please cite the original version:

Solli, G. S., Sandbakk, S. B., Noordhof, D. A., Ihalainen, J. K., & Sandbakk, Ø. (2020). Changes in Self-Reported Physical Fitness, Performance, and Side Effects Across the Phases of the Menstrual Cycle Among Competitive Endurance Athletes. *International Journal of Sports Physiology and Performance*, 15(9), 1324-1333. <https://doi.org/10.1123/ijsp.2019-0616>

Changes in self-reported physical fitness, performance, and side-effects across the phases of the menstrual cycle among competitive endurance athletes

Guro Strøm Solli^{1,2}, Silvana Bucher Sandbakk³, Dionne A. Noordhof², Johanna K. Ihalainen^{4,5}, Øyvind Sandbakk²

Original investigation

¹ Department of Sports Science and Physical Education, Nord University, Bodø, Norway

² Centre for Elite Sports Research, Department of Neuromedicine and Movement Science, Norwegian University of Science and Technology, Trondheim, Norway

³ Cardiac Exercise Research Group, Department of Circulation and Medical Imaging, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology, Trondheim, Norway

⁴ Neuromuscular Research Center, Faculty of Sport and Health Sciences, University of Jyväskylä, Finland

⁵ Department of Health Sciences, Swedish Winter Sports Research Centre, Mid Sweden University, Östersund, Sweden

Corresponding Author

Guro Strøm Solli
Department of Sports Science and Physical Education
Nord University,
8026 Bodø, Norway
E-mail: guro.s.solli@nord.no
Phone: +47 97660430

Preferred running head:

Running head
Physical fitness and performance across the menstrual cycle

Abstract Word Count
250

Text-Only Word Count
3954

Number of Figures and Tables
Figures: 4 and Tables: 2

Abstract

Purpose: To investigate changes in self-reported physical fitness, performance, and side-effects across the menstrual cycle (MC) phases among competitive endurance athletes, and to describe their knowledge and communication with coaches about the MC.

Methods: The responses of 140 participants (>18 years), competing in biathlon or cross-country skiing at the (inter)national level were analyzed. Data were collected via an online questionnaire addressing participants' competitive level, training volume, MC history, physical fitness and performance during the MC, MC-related side-effects, and knowledge and communication with coaches about the MC and its effects on training and performance.

Results: 50% and 71% of participants perceived improved and reduced fitness respectively, during specific MC-phases, whereas 42% and 49% perceived improved and reduced performance, respectively. Most athletes reported their worst fitness (47%) and performance (30%), and the highest number of side-effects during bleeding ($p<.01$; compared to all other phases), the phase following bleeding were considered the best phase for perceived fitness (24%, $p<.01$) and performance (18%, $p<.01$). Only 8% of participants reported to have sufficient knowledge about the MC in relation to training, and 27% communicated about it with their coach.

Conclusions: A high proportion of athletes perceived distinct changes in fitness, performance, and side-effects across the MC-phases, with their worst perceived fitness and performance during the bleeding phase. Because most athletes indicate a lack of knowledge about the MC's effect on training and performance and few communicate with coaches on the topic, we recommend that more time should be devoted to educating athletes and coaches.

Keywords: coaching, female athlete, hormonal contraceptives, sex hormones, training quality, coach education

Introduction

Differences in physical development between women and men accelerate from the onset of puberty, mainly due to changes in circulating levels of sex-specific hormones. In women aged ~13 to ~50 years, ovarian hormones fluctuate with defined phases of varying hormonal profiles during 21–35-day periods in an individual rhythm called the *menstrual cycle* (MC).^{1,2} Hormonal fluctuations during the MC have been reported to particularly influence ventilation, thermoregulation, and substrate metabolism^{3–6}, as well as causing negative side-effects such as pain, heavy menstrual bleeding, anemia, and mood changes.^{7,8} In theory, such physiological responses to hormonal fluctuations and their negative side-effects could influence the quality of training and endurance performance throughout the MC. However, the previous research on the influence of MC on objectively measured endurance performance are inconsistent.^{3,4,9–15} This is possibly due to methodological differences (e.g., divergent definitions of MC phases), the low number of available studies using quantified hormonal concentrations to verify MC phases,¹⁶ and the low number of studies with adequate sample size conducted on this topic.¹⁷ Furthermore, a substantial proportion of elite athletes are known to be susceptible to menstrual irregularities,^{18,19} which disrupt their hormone profiles and thereby make the interpretation of research findings challenging.

The available research on the athlete's perceived effect of the MC reports that 51% of elite marathon runners experienced an impact of their MC on training and performance.⁸ However, details on when runners performed best or worst during the cycle were not provided. Moreover, Martin et al.⁷ found that 77% of athletes not using hormonal contraceptives (HCs) reported negative MC-related symptoms (e.g., abdominal pains or cramps), mostly during the first days of bleeding. However, their sample included athletes from a range of sports, and they did not investigate whether the athletes had planned or adjusted their training to accommodate these negative side-effects. Consequently, specific information about the influence of the MC on perceived physical fitness and performance and the negative side-effects from a large sample of elite endurance athletes would provide important information.

An estimated 40–70% of female athletes use some type of HCs,^{7,18,20} with athletes perceiving in general more positive than negative effects of HC use.⁷ Examples of positive effects are the ability to predict or manipulate the bleeding period and the reduction of pain, while negative effects such as weight gain and irregular periods have also been reported.⁷ Women using combined oral contraceptives (OCs) have exhibited higher cortisol levels,²¹ lower maximal aerobic capacity,²² and less adaptation to sprint-interval training²³ than non-users, whereas endurance performance seems unaffected.^{14,24,25} It is currently unknown whether the varying doses and routes of administration of sex hormones in different HC preparations (e.g., OCs, implants, injections, transdermal patches, vaginal rings, and intrauterine systems) and types of HCs (e.g., estrogen–progestin and progestin-only types) will influence endurance performance.²⁶ However, negative side-effects have more often been reported for progestin-only than estrogen–progestin HCs.⁷ In addition, considerable individual variations in the type and severity of HC-related side-effects, as well as in reasons to start and stop using HCs, have been reported.⁷ Indeed, more specific knowledge about the use of HCs among competitive endurance athletes could help female athletes to optimize their training adaptations during the MC. Therefore, the primary aim of the current study was to investigate changes in self-reported physical fitness, performance, and side-effects during the different phases of the MC in competitive endurance athletes, and the influence of age (i.e., senior vs. junior athletes), performance level (i.e., international vs. national), and HC-use.

Another unclear factor is how much endurance athletes know about the MC and its possible effects on their training and performance. Furthermore, a large proportion of female athletes are coached by men,^{27,28} who, according to a previous study, are less knowledgeable about, and less comfortable with talking about MC irregularities than female coaches.²⁹ However, this has only been examined in a sample of high-school coaches whose knowledge and communication behaviors might differ from coaches of elite athletes. Moreover, the main topic of their questionnaire was the female athlete triad, not the MC. Consequently, research on how much endurance athletes and their coaches know and communicate about the MC remains necessary. Therefore, the secondary aim of the current study was to describe athletes' knowledge and communication with their coaches about the MC.

Methods

Participants

As cross-country skiing and biathlon are demanding endurance sports in which approximately 90% of training consists of aerobic endurance exercises,^{30,31} 184 elite female athletes from these sports were recruited between May and September 2018. All participants had to be >18 years old and competing at the national or international level. Ultimately, 140 elite endurance athletes completed the questionnaire, and their data were included in the final analysis (Figure 1). Of them, 59% (n=82) were cross-country skiers, and 41% (n=58) biathletes. The study was evaluated by the Regional Committee for Medical and Health Research Ethics (2018/50/REK-midt) and approved by the Norwegian Social Science Data Services. All participants were informed about the content and nature of the questions, and that they by agreeing to the terms and completing the questionnaire, had provided written informed consent for their information to be used in this study.

*Unspecified in combination with Microgynom® (n=1). **Unspecified copper based (n=1). ***Hormonal preparation without contraceptives (n=1).

Figure 1 – Sample characteristics and the prevalence of type, delivery method, and preparation of HCs used; HC, hormonal contraceptives; IUS, intrauterine system; OC, oral contraceptive.

Questionnaire

Data were collected via an online questionnaire (Questback, 2017) designed according to the study's aim and developed by an expert panel of former athletes, coaches, a physiologist, and researchers with experience from similar projects and relevant medical expertise. To ensure that participants understood the questions, a pilot study with eight participants was conducted before data collection commenced.

Designed to take 15–20 min to complete, the questionnaire contained 54 questions: 25 closed-ended questions, 11 questions asking for a numeric value, seven yes-or-no questions, three multiple-choice questions, and 11 open-ended questions. Participants reported their demographic information, aspects of training, competition level, menstrual history, physical fitness (perceived training quality), and performance (results on tests or competitions) during the MC, as well as MC-related negative side-effects. To ensure a uniform understanding of the MC's different phases, a simple four-phase definition of the MC was provided prior to questions regarding the different phases (Figure 2). The questionnaire also contained questions about the athletes' perceptions of their own and their coaches' knowledge of the MC in relation to training and how they communicated about the topic. All athletes answered the questions related to communication and knowledge about the MC (n=140), while all athletes who reported to have had their menarche answered the questions regarding physical fitness, performance and menstrual-related side effects across the different phases of the MC (n=139). Current HC users (n=78, 56%) were instructed to complete an additional set of in-depth questions about their experience with using HCs. Because the questionnaire was in Norwegian, a translating process was performed to ensure validity when interpreting the questions in English. First, the questionnaire was translated by one person that was fluent in English and had a good understanding of Norwegian. Thereafter, this version was back-translated independently by two persons who were fluent in Norwegian and had a good understanding of English. Thereafter, all three translators compared the original questionnaire with the one translated back and assessed if a word or several words reflected the same in both the original and the English version of the questionnaire.³²

Figure 2 – Definition of the menstrual cycle in connection to questions related to phases of the cycle.

Statistics

Questionnaire responses were summarized in numerical values to facilitate statistical analyses. To categorize free-text questions, two researchers performed independent content, frequency, and consistency analyses until consensus was reached. Direct verbatim quotations were used to inform interpretation. Descriptive data for continuous variables were recorded as means (*SD*) and for categorical variables as totals and percentages. For continuous variables, the Shapiro–Wilk test and standard visual inspection were used to examine the assumption of normality.

A binary group categorization was performed to assess potential differences in subgroups by age, including junior (i.e., 17–20 years old) versus senior athletes (i.e., 21–33 years old); performance level, including Level 1 (i.e., at least one ranking of 1–30 in international competitions or an overall ranking of 1–10 in the Norwegian National Cup) versus Level 2 (i.e., overall ranking of 11–50 in the Norwegian National Cup); and HC use status, including current HC users versus current non-HC users. Pairwise differences in sample characteristics between subgroups were assessed with independent samples *t*-tests and differences in proportions assessed with Pearson’s chi-squared tests.

The total score of side-effects was calculated as the sum of reported symptoms during each phase of the MC. Global differences in the number of side-effects across the phases were assessed with linear mixed-effects models involving MC-phase as a fixed factor and participant as a random factor. When significant *F*-values emerged, pairwise post hoc tests with Tukey’s adjustment were used. Model fit was examined with normal Q–Q plots of studentized residuals. Interactions of phase with age, performance level, and HC-use were examined to assess differences between subgroups.

All statistical tests were two-sided, and *p* values <.05 were considered statistically significant. Statistical analyses were conducted using the Statistical Package for the Social Sciences version 24.0 (SPSS Inc., Chicago, IL, USA) and Microsoft Excel 2016 (Microsoft Corporation, Redmond, WA, USA).

Results

The sample’s characteristics appear in Table 1 and summarized questionnaire responses in Supplementary Tables 1–5. The average age of menarche for all athletes was 13.9±2.0 years; 15% were more than 16 years old at menarche, and one 19-year-old athlete reported primary amenorrhea. Few athletes (4%) reported no bleeding periods during the previous year, 13% reported fewer than five periods, 17% reported 5–9, and 56% reported 10–15. Moreover, 30% experienced loss of menstrual bleeding in connection with high volumes of training and 23% in connection with large amounts of high-intensity training.

231 **Table 1 Age and training data (Mean±SD) for the 140 elite female cross-country skiers and biathletes included in this study.**

	Total (n=140)	Age group		<i>P-value</i>	Performance			Current HC-user		
		Junior (n=81)	Senior (n=59)		Level 1 (n=68)	Level 2 (n=72)	<i>P-value</i>	No (n=61)	Yes (n=78)	<i>P-value</i>
Age (years)	21.6±3.1	19.4±0.9	24.4±2.8	.000	22.4±3.5	20.8±2.5	.009	20.5 ± 2.3	22.4 ± 3.4	.000
Training volume (h/year)	575±148	523±109	620±163	.000	640±130	513±138	.000	570±130	579±162	.633
Weekly volume GP (h/wk)	13.6±3.9	12.7±3.5	14.5±4.1	.000	15.4±3.4	12.0±3.5	.000	13.4±3.7	13.9±4.0	.373
Weekly sessions GP (h/wk)	9.9±2.6	9.5±2.8	10.3±2.4	.013	10.4±2.0	9.0±2.7	.000	9.8±2.4	10.1±2.8	.481
Weekly HIT GP (h/wk)	2.4±0.8	2.3±0.8	2.4±0.8	.035	2.5±0.7	2.2±0.9	.014	2.2±0.8	2.4±0.9	.045
Weekly volume CP (h/wk)	10.1±3.0	9.6±2.4	10.7±3.3	.013	11.4±2.5	9.1±2.9	.000	10.0±3.0	10.4±2.9	.264
Weekly sessions CP (h/wk)	8.5±2.6	8.3±2.7	8.9±2.4	.014	9.5±2.5	7.8±2.4	.000	8.5±2.7	8.7±2.4	.247
Weekly HIT CP (h/wk)	2.6±0.8	2.6±0.8	2.7±0.8	.169	2.8±0.6	2.5±0.9	.008	2.6±0.7	2.7±0.9	.304

232 HC; hormonal contraceptives, Level 1; at least one ranking between 1-30 in world cup races and/or an overall ranking between 1-10 in the Norwegian National Cup, Level 2;
 233 at least and/or an overall ranking between 11-50 in the Norwegian National Cup, HIT; high-intensity training, GP; general preparation phase, CP; Competition phase.

Physical fitness, performance, and MC-related side-effects during the MC

Figure 3 illustrates the athletes' self-reported physical fitness and performance during the MC. Fifty and 71% of the athletes reported improved or reduced physical fitness during specific phases of the MC, respectively, whereas 42% and 49% reported improved or reduced performance, respectively. Global comparisons revealed that physical fitness and performance differed significantly by phase (both $p < .001$) and that the greatest proportion of athletes experience their worst fitness (47%) and performance (30%) during Phase 1 ($p < .01$ compared to all other groups). By contrast, the best physical fitness was reported most frequently during Phases 2 and 3 (24% and 14%, respectively; both $p < .01$ compared to Phases 1 or 4), as was best performance (18% and 18%, respectively; both $p < .01$ compared to Phases 1 or 4). Subgroup analyses revealed no significant differences between age groups, performance levels, or use of HCs (all $p > .05$). A large proportion of athletes indicated not to perceive improvement (50%) or reduction (29%) in physical fitness, or improvement (58%) or reduction (51%) in performance across the different phases of the MC (Figure 3).

The most frequently reported side-effects were stomach pain (83%) and bloating (63%, Figure 4), while 8% of the athletes had not experienced any MC-related side-effects in the last year. The number of side-effects differed significantly by phase ($p < .001$), with the highest number being reported in Phase 1 (3.6 ± 2.4), followed by Phases 4 (2.1 ± 2.1), 2 (0.5 ± 1.3), and 3 (0.3 ± 0.7 , $p < .05$ for all pairwise comparisons). Subgroup analyses revealed no significant interactions by age group, performance level, or use of HCs (all $p > .05$).

Fifty-two and 22% of the athletes altered their training at least once or more than 3 times, respectively, due to MC-related side-effects during the previous year. Only 7% of athletes planned their training according to their MC ($p < .001$). The most frequent reasons for altering training were stomach pain (40%) and lower-back pain (20%) (detailed information presented in Table 2).

Figure 3 A–D – The athletes' self-reported best (A) and worst (B) physical fitness, and the athletes' self-reported best (C) and worst (D) performance across the phases of the menstrual cycle.

Figure 4 – The athletes’ self-reported side-effects across the phases of the menstrual cycle.

Use of HCs

As shown in Figure 1, 56% of the athletes were using HCs at the time of data collection. HC-users were significantly older than non-users (22.4 vs. 20.5 years; $p<.01$), and 61% used estrogen–progestin HCs, 38% used progestin-only HCs, and 1% used an unspecified type of OC (Figure 1). OCs were the most widely used HCs, followed by intrauterine systems (15%), implants (9%), and vaginal rings (3%).

In response to follow-up questions, nearly all HC users (98%) used HCs throughout the entire year, and 33% used HCs to manipulate their timing of the MC. 17% of HC-users stated that HCs had positively affected their performance or physical fitness, 5% reported negative experiences, and 26% reported previously discontinuing their use of another type of HC that had compromised their performance (detailed information presented in Table 2).

Knowledge and communication about the MC

Overall, 8% of the athletes reported having sufficient knowledge about the MC in relation to athletic training and performance. Most athletes had communicated about training and the MC with other athletes (79%), friends (66%), and family members (56%), while only 27% had communicated with their coaches about the topic. Notably, 81% of the athletes’ coaches were men, and 19% were women; however, 44% of athletes with female coaches reported discussing the MC with their coaches, only 22% of ones with male coaches reported doing so. Among athletes who had not talked to their coaches about the MC and training, 63% did not want to do so, and 27% found broaching the subject difficult (reasons presented in Table 2).

296
297

Table 2 Overview of the analysis of open-end follow up questions about menstrual cycle-related adjustments of training, knowledge and communication about the menstrual cycle and the experiences of hormonal contraceptives

How have you changed your training according to MC-related side effects?¹⁾ Reduced the intensity (n=22) Cancelled/postponed session or taken a rest day (n=21) Reduced the duration (n=17) Postponed high-intensity sessions (n=10) Interrupted sessions (n=4) Changed exercise mode (n=4)	<i>"I did not train due to a bad physical shape or feeling miserable. I sometimes performed an easier type of session, and often missed a good training session."</i> <i>"I just get very tired and have poor physical shape on the first day of the bleeding phase. If it is an interval session or test, I try to postpone it because it always goes bad on these days."</i>
What would you like to learn in relation to the MC and training?²⁾ General information about how the MC can affect training (n=41) If it's possible to periodize training sessions after the MC to get more effect of the training (n=33) If the MC affects performance (n=30) If the MC can affect training adaptations (n=19) If/how HCs affect training and performance (n=9) If it is dangerous if the menstrual bleeding phase disappears (n=6) If there are menstrual phases during which you are more vulnerable for injuries (n=2) If there is something you can do to reduce pain (n=2)	<i>"If and to what extent the MC can affect exercise. For example, if I can benefit from exercising in a specific way, like more emphasis on high-intensity or strength sessions in a particular phase of the cycle. The same applies recovery after sessions; how does the MC affects this, and to what extent would the use of oral contraceptives affect training and recovery."</i> <i>"I have lost my period completely, so it would be nice to know if this is normal and whether it will be possible to have children in the future."</i>
Why do you find it difficult to talk to your coach about the MC?³⁾ Private, taboo, uncomfortable or embarrassing (n=11) My coach is a man (n=10) Don't know (n=7) Don't know the coach well enough (n=4) The coach lacks knowledge on this topic (n=3)	<i>"Feels like it's a taboo. I am afraid that the coach won't take it seriously and thinks I'm using it as an excuse."</i> <i>"I think I have more competence and knowledge about this topic than he."</i> <i>"Because he is a man."</i>
What knowledge about the MC and training do you think your coach lacks?⁴⁾ General information about how the MC can affect training (n=22) Don't know since we have not talked about this (n=16) If the MC can affect training adaptations or performance (n=13) That it leads to pain (n=3) How it affects the risk for injuries (n=1)	<i>"The difference between female and male athletes. I think there may be differences due to the MC that he is not aware of."</i> <i>"General lack of knowledge about the menstrual cycle"</i>
How has the use of HCs affected your performance at training or competitions?⁵⁾ Less pain (n=9) More tired (n=4) Don't need to worry about the bleedings (n=2) Gain of weight (n=2) Less bleeding (n=1) Mood swings (n=1)	<i>"Decreases pain and shortens the bleeding phase."</i> <i>"Positive: can skip my period in the competition season."</i> <i>"Gained 3 kg! When I quit using the pill, I lost weight and could run much easier uphill."</i>
Can you describe why you stopped using this type of HC?⁶⁾ Weight gain (n=7) Irregular MC(n=6) Increased pain (n=5) Mood swings (n=5) Lack of performance progress (n=2) Unsure if it could affect my training adaptations (n=1) Thrombosis (n=1) Stressful to remember to take the pill (n=1)	<i>"Gained weight. It negatively affected my performance."</i> <i>"Mostly because I felt out of balance, both physically and mentally."</i> <i>"Experienced discomfort during the bleeding period. Got irregular bleeding, weight gain and mood swings."</i>

MC; menstrual cycle, HC; hormonal contraceptives. The questions in the table were follow-up questions asked to all athletes answering ¹⁾that they had changed their training because of MC-related side effects ²⁾"No" at the question: "Do you think you have enough knowledge about how the MC can affect training and performance?", ³⁾"Yes" at the question: "Do you find it difficult to talk to your coach about the MC in relation to training and performance?" ⁴⁾"No" at the question: "Do you think your coach has enough knowledge about the MC in relation to training and performance?" ⁵⁾"Yes" at the question: Have you experienced that the HC affects your performance on training or competition? ⁶⁾"Yes" at the question: "Have you ever stopped using a HC, because you experienced it affected your physical fitness or performance?"

298
299
300
301

302

Discussion

We investigated changes in self-reported physical fitness, performance, and negative side-effects during the different phases of the MC among competitive endurance athletes, as well as the athletes' knowledge and communication with their coaches about this topic. The main findings of the current study were: 1) 50% and 71% of the athletes perceived improved or reduced physical fitness, respectively, during specific phases of the MC, whereas 42% and 49% reported improved and reduced performance, respectively; 2) a large proportion of athletes perceived no changes in physical fitness or performance across the MC; and 3) no differences in fitness, performance or negative side-effects by age, performance level, or HC-use emerged. Moreover, 4) only 8% of the athletes indicated having sufficient knowledge about the MC's effects on athletic training and performance, and 5) only 27% reported to communicate with their coaches about the topic.

Physical fitness, performance, and side-effects during the different phases of the MC

The result that approximately 50% of the athletes reported distinct changes in physical fitness and performance during the MC-phases is comparable to what Bruinvels et al.⁸ observed among marathon runners. Of the athletes who reported that the MC had affected their fitness or performance, significantly more reported reduced physical fitness or performance in Phase 1 (i.e., bleeding) than during the other three phases. Reduced physical fitness or performance during the MC has been associated with premenstrual symptoms or dysmenorrhea (i.e., menstrual cramps caused by uterine contractions).² Likewise, our athletes reported that negative side-effects of the MC most often occurred during Phase 1, followed by Phase 4 (i.e., 1–4 days before bleeding). The most common symptoms were stomach pain, bloating, and mood swings. Such findings align those of Martin et al.⁷, who reported the highest prevalence of side-effects during days 1 and 2 of Phase 1. Other researchers have observed higher training monotony and strain during the early stages of the MC than during the ovulatory phase, which they attributed to the increased prevalence of MC-related symptoms in the first half of the MC (i.e., follicular phase) compared to the second half (i.e., luteal phase).³³ Most likely due to the high incidence of side-effects in Phases 1 and 4, athletes in our sample reported the best physical fitness and performance during Phases 2 and 3. However, experimental research on endurance performance during the phases of the MC has produced mixed results; some researchers have observed better performance during the follicular phase^{11,15} or increased performance during the luteal phase,^{9,12} although most have reported no fluctuation in performance during the MC.^{3,4,10,13,14} Such inconsistent findings may stem from methodological differences,¹⁶ particularly in different definitions of the MC's phases. However, the substantial number of athletes in our study who reported distinct changes in performance during the MC highlights the need for additional research on the topic.

Despite the high incidence of symptoms of stomach pain (83%), only 22% of the athletes reported to repeatedly (i.e., >3 times/year) alter their training due to MC-related side-effects. By comparison, Martin et al.⁷ found that only 4% of athletes in different sports reported needing to refrain from exercise at certain points of their MC.⁷ In our study, the most frequent types of MC-related training adjustments were reduced intensity or duration, cancelled sessions and postponed high-intensity training sessions. To reduce the severity of negative side-effects, 52% of the athletes reported having used painkillers, which suggests that many athletes experience some degree of pain during the MC that can affect their physical fitness, performance, and training quality. However, it remains uncertain whether athletes take those medications to become able to perform planned training sessions and whether doing so affects subsequent

training adaptations. In response, monitoring the MC could likely provide information to guide the development of training schedules and optimize performance.

Period prevalence and HC use

The mean age at menarche (13.9 ± 2.0) was roughly the same as that previously reported by endurance athletes (13.8 ± 1.5),¹⁸ slightly higher than that of athletes from various sports (13.6 ± 1.4)⁷, and higher than that observed in non-athlete controls (13.0 ± 1.3).¹⁸ Whereas 15% of the athletes in our study reported primary amenorrhea (i.e., menarche at 16 years of age or older), only 11% of endurance athletes reported the same in an earlier study.¹⁸ Although it remains unclear whether delayed menarche derives from genetic factors, high volumes of training, or a focus on leanness,¹⁸ most non-HC users (56%) reported a prevalence of MCs within the normal range of 10–15 cycles per year. Notably, 35% of non-HC users reported fewer than nine periods in the previous year, which could indicate menstrual dysfunction.³⁴ Elite female athletes, particularly endurance athletes, are known to be susceptible to menstrual irregularities, often due to relative energy deficiencies associated with high volumes of training.³⁵ In line with that trend, 30% of the athletes in our study indicated the loss of periods in connection with high volumes of training and 23% with large amounts of high-intensity training. Although we did not assess energy intake or energy expenditure, high volumes of training and high amounts of high-intensity endurance training are associated with high energy expenditure and can prompt relative energy deficiencies. Elite endurance athletes and their coaches should therefore be aware of the risk of MC irregularities induced by high volumes of training and high amounts of high-intensity training. The prevention of MC irregularities should also be pursued, because primary and secondary amenorrhea can result in adverse health conditions, including reduced bone health.³⁵

The prevalence of HC use in our study (56%) exceeded that reported for the female population in Nordic countries (35–45%)³⁶ but fell within the 40–70% prevalence reported by elite athletes.^{7,18,20} Martin et al.⁷ observed that a higher proportion of athletes used estrogen–progestin HCs (61%) than progestin-only HCs (38%). This was also the case in our study, and may be explained by the lower proportion of negative side-effects reported with the use of estrogen–progestin versus progestin-only HCs.⁷ Martin et al.⁷ additionally reported that HC users were more likely to indicate positive than negative side-effects, which we also observed in our study. However, 26% of HC users reported previously discontinuing their use of other contraceptives because they had compromised their performance. Other researchers have highlighted a large individual response to HCs,⁷ possibly due to limited knowledge and communication about this topic.

Knowledge and communication about the MC

Only 8% of the athletes indicated having sufficient knowledge about how the MC affects athletic training and performance. Most coaches in women's sports are men,^{27,28} none of whom has personal experience with the MC, which may reduce the transfer of knowledge and communication about the MC and its possible effect on training and performance. In our study, 27% of the athletes reported that they had communicated about the MC with their coach during the previous year, with the percentage being higher when the coach was a woman (44%) instead of a man (22%). In line with those findings, a previous study reported that male coaches believed it was less important to ask athletes about menstrual irregularities, had less knowledge about the health risk associated with menstrual irregularities, and were less comfortable with communicating about menstrual irregularity than female coaches.²⁹ Furthermore, our data also

revealed that most of the athletes (63%) did not want to talk to their coaches about their MCs, which indicates that the topic continues to be regarded as taboo. Since menstrual dysfunctions are an important marker for relative energy deficit, a syndrome affecting many aspects of physiological functioning, health, and athletic performance,³⁵ it is important that athletes feel comfortable to discuss this topic with their coach. Furthermore, because of the high inter-individual variability in performance and side effects experienced by athletes during the MC, coach-athlete communication is important to safeguard the athlete's health as well as optimize training adaptations and performance. In response, increased attention should be paid to educating female athletes and their support teams about the MC and athletic training.

Limitations

Several limitations of the current study should be highlighted: 1) The data of athletes using different HCs were combined into one group, while the hormonal concentrations and perceived side-effects might differ between types of HC; 2) The statistical power was too low to make comparisons between the different types of HC; 3) Recall bias is a limitation of retrospective questionnaires; 4) Headaches or heavy menstrual bleeding, both of which are frequently reported side-effects of the MC,^{7,8} were not included as side-effects in the questionnaire; 5) The four-phase definition of the MC (Figure 2) has not been used in previous research, which makes comparisons to literature difficult, and; 6) The relationships between the changes in perceived physical fitness, performance and side-effects, and the concentration of hormones cannot be established. Therefore, we can not provide any recommendations regarding training and performance optimization during the specific phases of the MC.

Practical applications

- *Systematic monitoring of the MC:* Coaches should motivate their athletes to track their MC and MC-related symptoms and actively use this information in the evaluation of training quality, training adaptations and performance.
- *Conscious use of HC:* Coaches should make the athletes aware that HCs could affect their training response, both positively and negatively, and ensure that the athletes communicate about this with the medical doctor, so the preparations prescribed are optimal for their individual situation. Athletes should also systematically monitor their training response when starting with a (new) HC.
- *More communication:* Because of the high inter-individual variability in performance and side effects experienced by athletes during the MC, coach-athlete communication is important to safeguard the athlete's health as well as to optimize training adaptations and performance. The same applies for the use of HC.
- *Increased knowledge about the MC and HC:* Coaches should consult experts to ensure that they have enough knowledge to have an evidence-based dialogue about this topic with their athletes.
- *Education of athletes:* Increased attention should be paid to educating female athletes and their support teams about the MC, HC and athletic training.

Conclusions

A high proportion of athletes experienced distinct changes in fitness, performance, and side-effects across the MC-phases, with their worst perceived physical fitness, performance and most reported MC-related side-effects during bleeding. However, no differences by age, performance level, or HC use emerged, indicating these findings to be generalizable for the endurance athlete population. Because most athletes indicated a lack of knowledge about the MC's effect on athletic training and performance and few to communicate with their coaches about the topic, we recommend that more time should be devoted to educating athletes and coaches.

Acknowledgments

The authors would like to thank all of the athletes for their participation, as well as the Norwegian Ski Federation and the Norwegian Biathlon Federation for the cooperation on conducting this study.

References

1. Diaz A, Laufer MR, Breech LL. Menstruation in girls and adolescents: Using the menstrual cycle as a vital sign. *Pediatrics*. 2006;118(5):2245-2250.
2. Constantini NW, Dubnov G, Lebrun CM. The menstrual cycle and sport performance. *Clin Sports Med*. 2005;24(2):51-82.
3. Dombovy ML, Bonekat HW, Williams TJ, Staats BA. Exercise performance and ventilatory response in the menstrual cycle. *Med Sci Sports Exerc*. 1987;19(2):111-117.
4. Bemben DA, Salm PC, Salm AJ. Ventilatory and blood lactate responses to maximal treadmill exercise during the menstrual cycle. *J Sports Med Phys Fitness*. 1995;35(4):257-262.
5. Oosthuysen T, Bosch AN. The effect of the menstrual cycle on exercise metabolism: Implications for exercise performance in eumenorrhoeic women. *Sports Med*. 2010;40(3):207-227.
6. Pivarnik JM, Marichal CJ, Spillman T, Morrow JR, Jr. Menstrual cycle phase affects temperature regulation during endurance exercise. *J Appl Physiol* (1985). 1992;72(2):543-548.
7. Martin D, Sale C, Cooper SB, Elliott-Sale KJ. Period prevalence and perceived side effects of hormonal contraceptive use and the menstrual cycle in elite athletes. *Int J Sports Physiol Perform*. 2018;13(7):926-932.
8. Bruinvels G, Burden R, Brown N, Richards T, Pedlar C. The prevalence and impact of heavy menstrual bleeding (menorrhagia) in elite and non-elite athletes. *PLoS One*. 2016;11(2):e0149881.
9. Jurkowski JE, Jones NL, Toews CJ, Sutton JR. Effects of menstrual cycle on blood lactate, O₂ delivery, and performance during exercise. *J Appl Physiol Respir Environ Exerc Physiol*. 1981;51(6):1493-1499.
10. De Souza MJ, Maguire MS, Rubin KR, Maresh CM. Effects of menstrual phase and amenorrhea on exercise performance in runners. *Med Sci Sports Exerc*. 1990;22(5):575-580.
11. Campbell SE, Angus DJ, Febbraio MA. Glucose kinetics and exercise performance during phases of the menstrual cycle: Effect of glucose ingestion. *Am J Physiol Endocrinol Metab*. 2001;281(4):E817-825.

- 497 12. Oosthuyse T, Bosch AN, Jackson S. Cycling time trial performance during different
498 phases of the menstrual cycle. *Eur J Appl Physiol.* 2005;94(3):268-276.
- 499 13. Shaharudin S, Ghosh AK, Ismail AA. Anaerobic capacity of physically active
500 eumenorrheic females at mid-luteal and mid-follicular phases of ovarian cycle. *J Sports*
501 *Med Phys Fitness.* 2011;51(4):576-582.
- 502 14. Vaiksaar S, Jurimae J, Maestu J, et al. No effect of menstrual cycle phase and oral
503 contraceptive use on endurance performance in rowers. *J Strength Cond Res.*
504 2011;25(6):1571-1578.
- 505 15. Julian R, Hecksteden A, Fullagar HH, Meyer T. The effects of menstrual cycle phase
506 on physical performance in female soccer players. *PLoS One.* 2017;12(3):e0173951.
- 507 16. de Jonge X, Thompson B, Han A. Methodological recommendations for menstrual
508 cycle research in sports and exercise. *Med Sci Sports Exerc.* 2019.
- 509 17. Bruinvels G, Burden RJ, McGregor AJ, et al. Sport, exercise and the menstrual cycle:
510 Where is the research? *Br J Sports Med.* 2017;51(6):487-488.
- 511 18. Torstveit MK, Sundgot-Borgen J. Participation in leanness sports but not training
512 volume is associated with menstrual dysfunction: A national survey of 1276 elite
513 athletes and controls. *Br J Sports Med.* 2005;39(3):141.
- 514 19. De Souza MJ, Toombs RJ, Scheid JL, O'Donnell E, West SL, Williams NI. High
515 prevalence of subtle and severe menstrual disturbances in exercising women:
516 Confirmation using daily hormone measures. *Hum Reprod.* 2010;25(2):491-503.
- 517 20. Brynhildsen J, Lennartsson H, Klemetz M, Dahlquist P, Hedin B, Hammar M. Oral
518 contraceptive use among female elite athletes and age-matched controls and its relation
519 to low back pain. *Acta Obstet Gynecol Scand.* 1997;76(9):873-878.
- 520 21. Wikström-Frisén L, Nordström A, Mincheva-Nilsson L, Larsén K. Impact of season
521 and oral contraceptive use on cortisol levels in physically active women. *J Exerc Sports*
522 *Orthop.* 2016;3.
- 523 22. Lebrun CM, Petit MA, McKenzie DC, Taunton JE, Prior JC. Decreased maximal
524 aerobic capacity with use of a triphasic oral contraceptive in highly active women: A
525 randomised controlled trial. *Br J Sports Med.* 2003;37(4):315-320.
- 526 23. Schaumberg MA, Jenkins DG, Janse DEJXA, Emmerton LM, Skinner TL. Oral
527 contraceptive use dampens physiological adaptations to sprint interval training. *Med*
528 *Sci Sports Exerc.* 2017;49(4):717-727.
- 529 24. Rechichi C, Dawson B, Goodman C. Oral contraceptive phase has no effect on
530 endurance test. *Int J Sports Med.* 2008;29(4):277-281.
- 531 25. Myllyaho MM, Ihalainen JK, Hackney AC, et al. Hormonal contraceptive use does not
532 affect strength, endurance, or body composition adaptations to combined strength and
533 endurance training in women. *J Strength Cond Res.* 2018.
- 534 26. Elliott-Sale KJ, Hicks M. Hormonal-based contraception and the exercising female.
535 In: Forsyth J, Roberts C, eds. *The exercising female: Science and its application.*
536 Routledge; 2018:30-44.
- 537 27. Reade I, Rodgers W, Norman L. The under-representation of women in coaching: A
538 comparison of male and female canadian coaches at low and high levels of coaching.
539 *Int J Sports Sci Coach.* 2009;4(4).
- 540 28. Fasting K, Sisjord MK, Sand TS. Norwegian elite-level coaches: Who are they?
541 *Scandinavian Sport Studies Forum.* 2017;8:29-47.
- 542 29. Kroshus E, Sherman RT, Thompson RA, Sossin K, Austin SB. Gender differences in
543 high school coaches' knowledge, attitudes, and communication about the female athlete
544 triad. *Eat Disord.* 2014;22(3):193-208.
- 545 30. Solli GS, Tønnessen E, Sandbakk Ø. The training characteristics of the world's most
546 successful female cross-country skier. *Front Physiol.* 2017;8:1069.

31. Luchsinger H, Kocbach J, Ettema G, Sandbakk Ø. Comparison of the effects of performance level and sex on sprint performance in the biathlon world cup. *Int J Sports Physiol Perform*. 2018;13(3):360-366.
32. Gjersing L, Caplehorn JRM, Clausen T. Cross-cultural adaptation of research instruments: Language, setting, time and statistical considerations. *BMC med res methodol*. 2010;10:13-13.
33. Cristina-Souza G, Santos-Mariano AC, Souza-Rodrigues CC, et al. Menstrual cycle alters training strain, monotony, and technical training length in young. *J Sports Sci*. 2019:1-7.
34. Tenforde AS, Carlson JL, Chang A, et al. Association of the female athlete triad risk assessment stratification to the development of bone stress injuries in collegiate athletes. *Am J Sports Med*. 2017;45(2):302-310.
35. Mountjoy M, Sundgot-Borgen J, Burke L, et al. The ioc consensus statement: Beyond the female athlete triad-relative energy deficiency in sport (red-s). *Br J Sports Med*. 2014;48(7):491-497.
36. Lindh I, Skjeldestad FE, Gemzell-Danielsson K, et al. Contraceptive use in the nordic countries. *Acta Obstet Gynecol Scand*. 2017;96(1):19-28.